Streetbeat News

PDEX

Pro-Dex, Inc.

Industry

Medical - Instruments & Supplies

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.

Open

46.46

Mkt cap

162M

Volume

59K

High

50.00

P/E Ratio

25.34

52-wk high

59.60

Low

46.46

Div yield

N/A

52-wk low

16.84

Pro-Dex (NASDAQ:PDEX) reported strong Q1 2025 earnings, with EPS of $0.75 beating estimates by 158.62% and sales of $14.892M surpassing expectations by 23.07%. This marks a 24.74% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 8:46 pm

The article reports on the after-market session movements of various healthcare stocks. Notable gainers include Athira Pharma, Theriva Biologics, and Pro-Dex, while Biofrontera and BioRestorative Therapies were among the losers. Earnings reports influenced some stock movements.

Portfolio Pulse from Benzinga Insights

October 31, 2024 | 8:34 pm

Top Wall Street analysts have updated their price targets and ratings for several companies, including Starbucks, Pro-Dex, Summit Therapeutics, United States Steel, Costco, LGI Homes, Roblox, JetBlue, Colgate-Palmolive, and Nucor. Notably, BMO Capital raised Starbucks' price target from $100 to $110, maintaining an Outperform rating.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 1:05 pm

Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Pro-Dex (NASDAQ:PDEX) and raises the price target from $28 to $30.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 9:32 am

Pro-Dex (NASDAQ:PDEX) reported strong Q4 earnings, with EPS of $0.46 beating estimates by 31.43% and sales of $15.03M surpassing expectations by 41.75%. Both EPS and sales showed significant year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 8:23 pm

Pro-Dex (NASDAQ:PDEX) reported Q3 earnings of $0.19 per share, missing the consensus estimate of $0.35 by 45.71%, and a 47.22% decrease from last year's $0.36. However, their quarterly sales of $14.29M exceeded estimates by 8.28%, marking a 9.28% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:06 pm

Pro-Dex (NASDAQ:PDEX) reported Q2 earnings of $0.14 per share, missing the consensus estimate of $0.35 by 60%, and a 41.67% decrease from last year. However, sales of $12.59M beat the $11.50M estimate, marking an 11.58% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:58 pm

In Thursday's after-market session, several healthcare stocks showed notable movements. Xilio Therapeutics, Sensus Healthcare, Corvus Pharma, SenesTech, Coeptis Therapeutics, and Bright Green were among the gainers, with increases ranging from 4.99% to 10.5%. On the downside, BioXcel Therapeutics, Renalytix, Syra Health, SINTX Techs, NanoString Technologies, and Pro-Dex experienced declines between 8.28% and 42.1%. These movements reflect significant volatility in the healthcare sector, with specific companies showing substantial changes in their stock prices.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 9:31 pm

Pro-Dex (NASDAQ:PDEX) reported Q1 losses of $(0.17) per share, missing the analyst consensus estimate of $0.32 by 153.13%. This is a 158.62% decrease from the same period last year. However, the company's quarterly sales of $11.94 million beat the analyst consensus estimate of $11.20 million by 6.59%, a 7.68% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 8:57 pm

Pro-Dex shares are trading higher following the company's announcement of better-than-expected Q4 EPS results.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:53 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.